SG10201508035TA - Inhibitors of bruton's tyrosine kinase - Google Patents
Inhibitors of bruton's tyrosine kinaseInfo
- Publication number
- SG10201508035TA SG10201508035TA SG10201508035TA SG10201508035TA SG10201508035TA SG 10201508035T A SG10201508035T A SG 10201508035TA SG 10201508035T A SG10201508035T A SG 10201508035TA SG 10201508035T A SG10201508035T A SG 10201508035TA SG 10201508035T A SG10201508035T A SG 10201508035TA
- Authority
- SG
- Singapore
- Prior art keywords
- bruton
- inhibitors
- tyrosine kinase
- tyrosine
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/692,870 US7732454B2 (en) | 2006-09-22 | 2007-03-28 | Inhibitors of Bruton's tyrosine kinase |
US11/964,285 US7825118B2 (en) | 2006-09-22 | 2007-12-26 | Inhibitors of bruton's tyrosine kinase |
US1712507P | 2007-12-27 | 2007-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201508035TA true SG10201508035TA (en) | 2015-10-29 |
Family
ID=39808864
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201508035TA SG10201508035TA (en) | 2007-03-28 | 2008-03-27 | Inhibitors of bruton's tyrosine kinase |
SG10202107066WA SG10202107066WA (en) | 2007-03-28 | 2008-03-27 | Inhibitors of bruton's tyrosine kinase |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202107066WA SG10202107066WA (en) | 2007-03-28 | 2008-03-27 | Inhibitors of bruton's tyrosine kinase |
Country Status (14)
Country | Link |
---|---|
EP (6) | EP2560007A1 (fr) |
JP (2) | JP5347202B2 (fr) |
KR (1) | KR101425248B1 (fr) |
CN (2) | CN103319488A (fr) |
AU (1) | AU2008232762B2 (fr) |
BR (1) | BRPI0810086B1 (fr) |
CA (4) | CA3143428A1 (fr) |
EA (1) | EA017865B1 (fr) |
ES (1) | ES2562215T3 (fr) |
IL (8) | IL295053A (fr) |
MX (2) | MX2009010284A (fr) |
NZ (1) | NZ579911A (fr) |
SG (2) | SG10201508035TA (fr) |
WO (1) | WO2008121742A2 (fr) |
Families Citing this family (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
JP2009528280A (ja) | 2006-02-16 | 2009-08-06 | シェーリング コーポレイション | Erkインヒビターとしてのピロリジン誘導体 |
EP2081435B1 (fr) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibiteurs de la tyrosine kinase de bruton |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP2560007A1 (fr) * | 2007-03-28 | 2013-02-20 | Pharmacyclics, Inc. | Identification des Inhibiteurs de la tyrosine kinase de bruton |
EP2260031B1 (fr) | 2008-02-21 | 2015-10-07 | Merck Sharp & Dohme Corp. | Composés inhibiteurs de la voie erk |
EP3311818A3 (fr) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibiteurs de tyrosine-kinase de bruton pour le traitement de tumeurs solides |
US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
WO2011019780A1 (fr) * | 2009-08-11 | 2011-02-17 | Bristol-Myers Squibb Company | Azaindazoles comme modulateurs de la kinase btk et leur utilisation |
US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
MX2012013622A (es) | 2010-05-31 | 2013-02-01 | Ono Pharmaceutical Co | Derivado de purinona. |
WO2011153514A2 (fr) * | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk) |
AU2015275321B2 (en) * | 2010-06-03 | 2018-03-15 | Pharmacyclics Llc | The use of inhibitors of Bruton's tyrosine kinase (Btk) |
PL2710005T3 (pl) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
HUE059230T2 (hu) * | 2011-06-10 | 2022-10-28 | Merck Patent Gmbh | Vegyületek és eljárások BTK-inhibitor aktivitású pirimidin és piridin vegyületek elõállítására |
BR112013033534A2 (pt) * | 2011-06-28 | 2017-02-07 | Pharmacyclics Inc | métodos e composições para inibição de reabsorção de osso |
CN103732596B (zh) | 2011-07-08 | 2016-06-01 | 诺华股份有限公司 | 吡咯并嘧啶衍生物 |
WO2013010136A2 (fr) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibiteurs de tyrosine kinase de bruton |
WO2013010869A1 (fr) * | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk |
EP2548877A1 (fr) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK |
PE20141681A1 (es) * | 2011-07-19 | 2014-11-14 | Merck Sharp And Dohme B V | Inhibidores de btk |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
RU2622391C2 (ru) * | 2011-11-03 | 2017-06-15 | Ф. Хоффманн-Ля Рош Аг | Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона |
BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
KR20130076046A (ko) * | 2011-12-28 | 2013-07-08 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
SG2014009286A (en) * | 2012-01-19 | 2014-04-28 | Taiho Pharmaceutical Co Ltd | 3,5-disubstituted alkynylbenzene compound and salt thereof |
US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
WO2013125709A1 (fr) * | 2012-02-23 | 2013-08-29 | 大鵬薬品工業株式会社 | Composé à cycle fusionné de quinolyl-pyrrolo-pyrimidyl ou un sel associé |
CN104169260A (zh) * | 2012-03-09 | 2014-11-26 | 卡尔那生物科学株式会社 | 新三嗪衍生物 |
US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
IN2014MN02338A (fr) * | 2012-05-31 | 2015-08-14 | Pharmascience Inc | |
NZ702548A (en) | 2012-06-04 | 2015-11-27 | Pharmacyclics Llc | Crystalline forms of a bruton’s tyrosine kinase inhibitor |
CA2782774A1 (fr) * | 2012-07-06 | 2014-01-06 | Pharmascience Inc. | Inhibiteurs de proteine kinase |
JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異 |
BR112015002590A2 (pt) | 2012-08-10 | 2019-08-06 | Boehringer Ingelheim Int | compostos heteroaromáticos como inibidores de tirosina cinase de bruton (btk) |
JP2015526520A (ja) * | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Itk阻害剤としてのベンズイミダゾール誘導体 |
ES2731833T3 (es) | 2012-09-10 | 2019-11-19 | Principia Biopharma Inc | Compuestos pirazolopirimidínicos comos inhibidores de cinasas |
MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
US20140206681A1 (en) | 2013-01-23 | 2014-07-24 | Ronald M. Kim | Btk inhibitors |
AU2014219754B2 (en) | 2013-02-22 | 2016-05-05 | Taiho Pharmaceutical Co., Ltd. | Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
EP2970163B1 (fr) * | 2013-03-14 | 2018-02-28 | Boehringer Ingelheim International GmbH | Dérivés de 5-thiazolecarboxamide et leur utilisation en tant qu'inhibiteurs de la btk |
DK2970291T3 (da) * | 2013-03-15 | 2022-08-01 | Janssen Pharmaceutica Nv | Fremgangsmåder og mellemprodukter til fremstilling af et medikament |
EP2970300B1 (fr) | 2013-03-15 | 2018-05-16 | Boehringer Ingelheim International GmbH | Composés hétéroaromatiques en tant qu'inhibiteurs btk |
CA2901542C (fr) * | 2013-04-02 | 2018-02-13 | F. Hoffmann-La Roche Ag | Inhibiteurs de la tyrosine kinase de bruton |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
CN105408334B (zh) * | 2013-05-21 | 2017-10-10 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的取代的吡唑并嘧啶类化合物 |
CA2917167A1 (fr) | 2013-07-02 | 2015-01-08 | Pharmacyclics Llc | Composes purinones comme inhibiteurs de kinase |
US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
PL3023100T3 (pl) * | 2013-07-18 | 2019-07-31 | Taiho Pharmaceutical Co., Ltd. | Lek przeciwnowotworowy do okresowego podawania inhibitora FGFR |
JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
NO2947086T3 (fr) * | 2013-08-12 | 2018-06-02 | ||
CA2920534A1 (fr) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methodes de traitement d'un cancer amplifie par her2 |
SI3052476T1 (sl) | 2013-09-30 | 2020-12-31 | Guangzhou Innocare Pharma Tech Co., Ltd. | Substituirani nikotinimidni inhibitorji BTK in njihova priprava in uporaba pri zdravljenju raka, vnetja in avtoimunske bolezni |
PE20160560A1 (es) | 2013-09-30 | 2016-06-09 | Pharmacyclics Llc | DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK) |
US9795604B2 (en) | 2013-10-25 | 2017-10-24 | Pharmacyclics Llc | Methods of treating and preventing graft versus host disease |
CA2833867A1 (fr) * | 2013-11-21 | 2015-05-21 | Pharmascience Inc. | Inhibiteurs de proteine kinase |
US10328080B2 (en) | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
WO2015095099A1 (fr) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de btk |
WO2015095102A1 (fr) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de btk |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
US9828364B2 (en) | 2014-01-29 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as BTK inhibitors |
EA201691302A1 (ru) | 2014-02-03 | 2017-03-31 | Кадила Хелзкэр Лимитед | Новые гетероциклические соединения |
SG11201606858RA (en) | 2014-02-21 | 2016-09-29 | Principia Biopharma Inc | Salts and solid form of a btk inhibitor |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
JP6528779B2 (ja) | 2014-03-25 | 2019-06-12 | 小野薬品工業株式会社 | びまん性大細胞型b細胞リンパ腫の予防および/または治療剤 |
WO2015181633A2 (fr) | 2014-04-11 | 2015-12-03 | Acerta Pharma B.V. | Procédés de blocage de la voie de signalisation cxcr4/sdf-1 à l'aide d'inhibiteurs de la tyrosine kinase de bruton |
CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
CN106458919B (zh) * | 2014-05-13 | 2019-03-15 | 广东东阳光药业有限公司 | 一种中间体的制备方法 |
CN104086551B (zh) * | 2014-06-06 | 2016-09-21 | 人福医药集团股份公司 | 化合物及其制备方法和用途 |
GB201410430D0 (en) * | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
WO2015193740A2 (fr) | 2014-06-17 | 2015-12-23 | Acerta Pharma B.V. | Combinaisons thérapeutiques d'un inhibiteur de la tkb, d'un inhibiteur de la pi3k et/ou d'un inhibiteur de la jak-2 |
CN109970741B (zh) | 2014-07-07 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 作为蛋白激酶抑制剂的氨基哒嗪酮化合物 |
US9533991B2 (en) | 2014-08-01 | 2017-01-03 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
JP2017523206A (ja) | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
CN105461720B (zh) * | 2014-08-08 | 2019-08-06 | 南京圣和药业股份有限公司 | 吗啉类酪氨酸激酶抑制剂 |
HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
CA2965559A1 (fr) * | 2014-10-30 | 2016-05-06 | Sandoz Ag | Acrylamides actifs |
CN104407067B (zh) * | 2014-11-17 | 2016-01-20 | 广东东阳光药业有限公司 | 依鲁替尼及其异构体的检测方法 |
CN104447761A (zh) * | 2014-11-27 | 2015-03-25 | 广东东阳光药业有限公司 | 一种吡唑衍生物的制备方法 |
MA41197B1 (fr) | 2014-12-18 | 2021-01-29 | Principia Biopharma Inc | Traitement de le pemphigus |
MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
CN105837576B (zh) | 2015-01-14 | 2019-03-26 | 湖北生物医药产业技术研究院有限公司 | Btk抑制剂 |
CN104557945B (zh) * | 2015-01-27 | 2017-08-04 | 安润医药科技(苏州)有限公司 | 依鲁替尼合成方法 |
WO2016127915A1 (fr) * | 2015-02-12 | 2016-08-18 | 上海度德医药科技有限公司 | Procédé de préparation d'ibrutinib |
BR122023020985A2 (pt) | 2015-03-03 | 2023-12-26 | Pharmacyclics Llc | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
WO2016151438A1 (fr) * | 2015-03-20 | 2016-09-29 | Sun Pharmaceutical Industries Limited | Procédé de préparation d'ibrutinib |
MA41828A (fr) * | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
MA41827A (fr) * | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
CN111393446B (zh) | 2015-03-31 | 2022-12-20 | 大鹏药品工业株式会社 | 3,5-二取代的苯炔基化合物晶体 |
CN106146511A (zh) * | 2015-04-03 | 2016-11-23 | 安润医药科技(苏州)有限公司 | 吡唑并嘧啶衍生物、制备方法、药物组合物及用途 |
US10239879B2 (en) | 2015-04-09 | 2019-03-26 | Ono Pharmaceutical Co., Ltd. | Process for producing purinone derivative |
CN106146512B (zh) * | 2015-04-09 | 2018-07-17 | 北京睿创康泰医药研究院有限公司 | 依鲁替尼的制备方法 |
CN104844573A (zh) * | 2015-04-17 | 2015-08-19 | 中国药科大学 | 嘧啶类btk抑制剂、其制备方法及医药用途 |
US20180305350A1 (en) * | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
EP3317281B1 (fr) | 2015-07-02 | 2020-04-22 | Acerta Pharma B.V. | Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
LV15201B (lv) | 2015-08-31 | 2017-07-20 | Latvijas Organiskās Sintēzes Institūts | Ibrutiniba izejvielas iegūšanas paņēmiens |
PL3345907T3 (pl) * | 2015-09-01 | 2020-09-07 | Taiho Pharmaceutical Co., Ltd. | Związki pirazolo[3,4-d]pirymidynowe lub ich sole |
MA41559A (fr) * | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
TW201722957A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產(第二)有限公司 | 化學化合物 |
ES2929528T3 (es) | 2015-09-16 | 2022-11-29 | Loxo Oncology Inc | Derivados de pirazolopirimidina como inhibidores de BTK para el tratamiento del cáncer |
EA034561B1 (ru) | 2015-12-16 | 2020-02-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний |
LT3390395T (lt) | 2015-12-16 | 2020-11-25 | Loxo Oncology, Inc. | Junginiai, naudingi kaip kinazės inhibitoriai |
KR20180099787A (ko) * | 2016-01-05 | 2018-09-05 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Btk 키나아제 억제제의 결정질 형태 및 이의 제조 방법 |
US10570118B2 (en) | 2016-01-13 | 2020-02-25 | Boehringer Ingelheim International Gmbh | Isoquinolones as BTK inhibitors |
CN106995446B (zh) * | 2016-01-22 | 2021-07-02 | 山东新时代药业有限公司 | 布鲁顿酪氨酸激酶抑制剂制备方法 |
US10435409B2 (en) | 2016-02-04 | 2019-10-08 | Shilpa Medicare Limited | Process for the preparation of ibrutinib |
WO2017133630A1 (fr) * | 2016-02-05 | 2017-08-10 | 北京盛诺基医药科技有限公司 | Inhibiteur de la tyrosine kinase de bruton |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
AU2017240609B2 (en) | 2016-03-31 | 2021-07-15 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
US11564929B2 (en) | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
ES2904880T3 (es) | 2016-05-20 | 2022-04-06 | Lilly Co Eli | Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 |
CN106083860A (zh) * | 2016-06-23 | 2016-11-09 | 艾美科健(中国)生物医药有限公司 | 一种依鲁替尼中间体的合成与纯化工艺 |
IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
JP6715357B2 (ja) * | 2016-06-30 | 2020-07-01 | 杭州三因泰医薬科技有限公司Hangzhou Sanyintai Pharmaceutical Technology Co., Ltd. | イミダゾピリジンアミンフェニル誘導体およびその使用 |
CN107759602B (zh) * | 2016-08-17 | 2020-04-21 | 中国科学院上海药物研究所 | 含有共轭联烯结构的化合物、其药物组合物和用途 |
CN108368119B (zh) * | 2016-08-17 | 2019-04-23 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制酪氨酸激酶活性的稠合双环类化合物 |
EP3509599A4 (fr) * | 2016-09-08 | 2020-02-19 | Sabila Biosciences LLC | Composés 1,2-dithiolane utiles dans la neuroprotection, les maladies et les états auto-immuns et cancéreux |
JP2019529419A (ja) | 2016-09-19 | 2019-10-17 | エムイーアイ ファーマ,インク. | 併用療法 |
WO2018071307A1 (fr) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Traitement ciblé de lymphome à cellules t matures |
EP3543239A4 (fr) * | 2016-11-15 | 2019-09-25 | Hangzhou Hertz Pharmaceutical Co., Ltd. | Inhibiteur sélectif de la tyrosine kinase de bruton et son utilisation |
JOP20190113A1 (ar) * | 2016-11-18 | 2019-05-15 | Biocad Joint Stock Co | مثبطات بروتون تيروزين كيناز |
CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
CN106588937B (zh) | 2017-01-16 | 2018-09-21 | 东莞市真兴贝特医药技术有限公司 | 咪唑并吡嗪类化合物及其制备方法和应用 |
CA3054403A1 (fr) | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibiteurs de la tyrosine kinase de bruton |
EP3585789A1 (fr) | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibiteurs de tyrosine kinase de bruton |
BR112019019588A2 (pt) * | 2017-03-22 | 2020-04-22 | Suzhou Baijibugong Pharmaceutical Tech Co Ltd | composto, composição farmacêutica, método para tratar uma doença autoimune, composição farmacêutica para prevenir ou tratar cânceres, tumores, doenças inflamatórias, doenças autoimunes ou doença imunologicamente mediada, e método para tratar uma doença autoimune, cânceres, tumores, doenças inflamatórias ou doenças imunologicamente mediadas |
CN108727230B (zh) * | 2017-04-21 | 2021-03-23 | 江苏希迪制药有限公司 | 依鲁替尼中间体及其制备方法 |
CN107043366B (zh) * | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
CN109111446B (zh) | 2017-06-22 | 2021-11-30 | 上海度德医药科技有限公司 | 一种具有药物活性的杂芳基化合物 |
CN107602564B (zh) * | 2017-09-20 | 2019-08-30 | 南京亘泰医药技术有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
US11100492B2 (en) | 2018-02-19 | 2021-08-24 | Peter Garrett | General purpose re-loadable card aggregation implementation |
WO2019177902A1 (fr) * | 2018-03-10 | 2019-09-19 | Yale University | Modulateurs de protéolyse de btk et procédés d'utilisation |
CA3094431C (fr) | 2018-03-19 | 2023-06-27 | Taiho Pharmaceutical Co., Ltd. | Composition pharmaceutique comprenant du sulfate d'alkyle de sodium |
MX2020010437A (es) | 2018-04-05 | 2021-01-29 | Sumitomo Pharma Oncology Inc | Inhibidores de axl cinasa y uso de los mismos. |
US20210113562A1 (en) | 2018-04-13 | 2021-04-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
US20210113568A1 (en) | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
CA3103995A1 (fr) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci |
CN111440172B (zh) * | 2019-01-17 | 2022-02-11 | 暨南大学 | 丙烯酰胺类化合物及其应用 |
CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药(上海)有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
EP3924351A4 (fr) | 2019-02-12 | 2022-12-21 | Sumitomo Pharma Oncology, Inc. | Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020252397A1 (fr) * | 2019-06-12 | 2020-12-17 | Baylor College Of Medicine | Chimères ciblant la protéolyse à petites molécules et leurs méthodes d'utilisation |
DK4036095T3 (da) * | 2019-09-26 | 2024-03-04 | Jumbo Drug Bank Co Ltd | 4-fluor-1h-pyrazolo[3,4-c]pyridinderivater som selektive bruton-tyrosinkinase- (btk) inhibitorer til behandlingen af b-cellelymfom og autoimmunsygdomme |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
WO2021180103A1 (fr) * | 2020-03-11 | 2021-09-16 | Beigene, Ltd. | Dégradation de la tyrosine kinase de bruton (btk) par conjugaison d'inhibiteurs de btk avec un ligand de ligase e3 et procédés d'utilisation |
WO2021184154A1 (fr) | 2020-03-16 | 2021-09-23 | Flash Therapeutics, Llc | Composés pour le traitement ou l'inhibition de la récurrence d'une leucémie myéloïde aiguë |
US20230382900A1 (en) * | 2020-10-30 | 2023-11-30 | Newave Pharmaceutical Inc. | Inhibitors of btk |
CN112574216B (zh) * | 2020-12-16 | 2022-03-08 | 天津济坤医药科技有限公司 | 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 |
CN113004246B (zh) * | 2021-02-22 | 2022-02-01 | 广西医科大学 | 1,3,5-三嗪-2-胺-4,6取代衍生物或其药学上可接受的盐和用途 |
CN113402523B (zh) * | 2021-07-13 | 2022-07-12 | 西安交通大学 | 一种靶向肥大细胞MrgX2小分子荧光探针及制备方法和应用 |
CN114195790B (zh) * | 2021-11-18 | 2023-01-06 | 江苏阿尔法药业股份有限公司 | 一种依鲁替尼的合成方法 |
CN114276355B (zh) * | 2022-01-26 | 2023-04-07 | 江苏阿尔法药业股份有限公司 | 一种依鲁替尼的制备方法 |
CN114605418B (zh) * | 2022-03-15 | 2023-09-05 | 广东医科大学附属医院 | 一类具有抗肿瘤活性的依鲁替尼丙烯酰胺类衍生物及其合成方法与应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
AU3176297A (en) * | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
CA2283961A1 (fr) * | 1997-03-19 | 1998-09-24 | Basf Aktiengesellschaft | Pyrrolo [2,3] pyrimidines et leur utilisation comme inhibiteurs de la tyrosine kinase |
US6303652B1 (en) * | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
US20050287596A9 (en) * | 1998-06-26 | 2005-12-29 | Braisted Andrew C | Novel ligands and libraries of ligands |
US6335155B1 (en) * | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6998233B2 (en) * | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
IL148718A0 (en) | 1999-09-17 | 2002-09-12 | Abbott Gmbh & Co Kg | Pyrazolopyrimidines as therapeutic agents |
US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
CN1523991A (zh) * | 2001-08-10 | 2004-08-25 | ��˹��ŵ�� | 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途 |
JP4391237B2 (ja) * | 2001-11-21 | 2009-12-24 | サネシス ファーマシューティカルズ, インコーポレイテッド | リガンド発見のための方法 |
US20050084905A1 (en) * | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
GB2388594A (en) * | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
GB0303910D0 (en) * | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
US7687506B2 (en) * | 2003-04-11 | 2010-03-30 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
EP1473039A1 (fr) * | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Utilisation d'inhibiteurs et d'oligonucleotitides antisense de BTK pour le traitement de la mastocytose proliferative |
US7405295B2 (en) * | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
JP2005089352A (ja) * | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
JP4916883B2 (ja) * | 2003-10-15 | 2012-04-18 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
ITMI20041314A1 (it) * | 2004-06-30 | 2004-09-30 | Nuvera Fuel Cells Europ Srl | Dispositivo di raffreddamento per celle a combustibili a membrana |
AR053090A1 (es) * | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
EP1802602A1 (fr) * | 2004-09-28 | 2007-07-04 | Janssen Pharmaceutica N.V. | Antagonistes anti-ccr2 a base de dipiperidine substituee |
EP1812442A2 (fr) * | 2004-11-10 | 2007-08-01 | CGI Pharmaceuticals, Inc. | Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procédés de fabrication et d'utilisation correspondants |
EP1891066B1 (fr) * | 2005-05-13 | 2010-12-22 | Irm, Llc | Composes et compositions convenant comme inhibiteurs de proteine kinase |
CN102603581B (zh) * | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
MX2008008642A (es) * | 2006-01-13 | 2008-09-12 | Pharmacyclics Inc | Inhibidores de las tirosina cinasas y usos de los mismos. |
CA2858520A1 (fr) * | 2006-05-18 | 2007-11-29 | Pharmacyclics Inc. | Inhibiteurs de kinases intracellulaires |
EP2081435B1 (fr) * | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibiteurs de la tyrosine kinase de bruton |
CA2668286C (fr) * | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Sonde d'activite de la tyrosine kinase de bruton et son procede d'utilisation |
EP2560007A1 (fr) * | 2007-03-28 | 2013-02-20 | Pharmacyclics, Inc. | Identification des Inhibiteurs de la tyrosine kinase de bruton |
-
2008
- 2008-03-27 EP EP12172843A patent/EP2560007A1/fr not_active Withdrawn
- 2008-03-27 CA CA3143428A patent/CA3143428A1/fr active Pending
- 2008-03-27 EP EP08744513.6A patent/EP2139487B1/fr active Active
- 2008-03-27 BR BRPI0810086-1A patent/BRPI0810086B1/pt active IP Right Grant
- 2008-03-27 AU AU2008232762A patent/AU2008232762B2/en active Active
- 2008-03-27 EP EP12172842.2A patent/EP2561875A3/fr not_active Withdrawn
- 2008-03-27 EP EP15170739.5A patent/EP2954900A1/fr not_active Withdrawn
- 2008-03-27 KR KR1020097022436A patent/KR101425248B1/ko active IP Right Grant
- 2008-03-27 CA CA3001152A patent/CA3001152A1/fr not_active Abandoned
- 2008-03-27 MX MX2009010284A patent/MX2009010284A/es active IP Right Grant
- 2008-03-27 IL IL295053A patent/IL295053A/en unknown
- 2008-03-27 JP JP2010501231A patent/JP5347202B2/ja active Active
- 2008-03-27 SG SG10201508035TA patent/SG10201508035TA/en unknown
- 2008-03-27 EP EP12172841A patent/EP2548558A1/fr not_active Withdrawn
- 2008-03-27 WO PCT/US2008/058528 patent/WO2008121742A2/fr active Application Filing
- 2008-03-27 NZ NZ579911A patent/NZ579911A/en unknown
- 2008-03-27 CN CN2013101673466A patent/CN103319488A/zh active Pending
- 2008-03-27 ES ES08744513.6T patent/ES2562215T3/es active Active
- 2008-03-27 EA EA200901313A patent/EA017865B1/ru unknown
- 2008-03-27 EP EP12172840A patent/EP2543375A1/fr not_active Withdrawn
- 2008-03-27 CA CA2874756A patent/CA2874756C/fr active Active
- 2008-03-27 SG SG10202107066WA patent/SG10202107066WA/en unknown
- 2008-03-27 CN CN2008800147600A patent/CN101674834B/zh active Active
- 2008-03-27 CA CA2681756A patent/CA2681756C/fr active Active
-
2009
- 2009-09-24 IL IL201176A patent/IL201176A/en active IP Right Grant
- 2009-09-24 MX MX2019005150A patent/MX2019005150A/es unknown
-
2013
- 2013-08-01 JP JP2013160858A patent/JP5994051B2/ja active Active
-
2015
- 2015-06-03 IL IL239156A patent/IL239156A0/en unknown
- 2015-06-03 IL IL239155A patent/IL239155A0/en unknown
- 2015-06-03 IL IL239154A patent/IL239154A0/en unknown
-
2018
- 2018-01-18 IL IL257017A patent/IL257017A/en unknown
-
2019
- 2019-05-20 IL IL266741A patent/IL266741A/en unknown
-
2021
- 2021-01-14 IL IL280173A patent/IL280173A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL266741A (en) | Broton tyrosine kinase inhibitors | |
HK1254663A1 (zh) | 用於實體腫瘤的治療的布魯頓酪氨酸激酶的抑制劑 | |
ZA201301679B (en) | Inhibitors of bruton's tyrosine kinase | |
ZA201202552B (en) | Inhibitors of bruton's tyrosine kinase | |
PT2473049T (pt) | Inibidores de tirosina quinase de bruton | |
CY2015016I2 (el) | Αναστολεις της κινασης τυροσινης του bruton | |
ZA201300705B (en) | Inhibitors of bruton's tyrosine kinase | |
ZA201209381B (en) | The use of inhibitors of bruton's tyrosine kinase (btk) | |
EP2114983A4 (fr) | Inhibiteurs des recepteurs axl a activite tyrosine kinase et procedes de fabrication et d'utilisation de ceux-ci | |
ZA201004055B (en) | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors | |
AP2470A (en) | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | |
EP2040546A4 (fr) | Inhibiteurs de tyrosine kinase | |
ZA200900019B (en) | Tyrosine kinase inhibitors | |
IL187895A0 (en) | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | |
ZA200710136B (en) | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | |
AU2013276959B2 (en) | Inhibitors of Bruton's tyrosine kinase |